公开(公告)号：WO2009005471A1

公开(公告)日：2009-01-08

申请号：PCT/SE2008/050839

申请日：2008-07-04

Applicant: ASTRAZENECA AB ,  ASTEX THERAPEUTICS LTD ,  HOLENZ, Jörg ,  KERS, Annika ,  KOLMODIN, Karin ,  ROTTICCI, Didier ,  RAKOS, Laszlo ,  HELLBERG, Sven

Inventor： HOLENZ, Jörg ,  KERS, Annika ,  KOLMODIN, Karin ,  ROTTICCI, Didier ,  RAKOS, Laszlo ,  HELLBERG, Sven

IPC: C07D401/04 ,  A61K31/4427 ,  A61K31/506 ,  A61P25/16 ,  A61P25/28 ,  C07D403/04

CPC classification number: C07D401/14 ,  C07D401/04

Abstract: This invention relates to novel compounds having the structural formula I below: (Formula I), and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Abstract translation: 本发明涉及具有以下结构式I的新化合物：（式I）及其药学上可接受的盐，组合物和使用方法。 这些新化合物提供了认知障碍，阿尔茨海默病，神经变性和痴呆症的治疗或预防。

公开(公告)号：WO2008076043A1

公开(公告)日：2008-06-26

申请号：PCT/SE2007/001116

申请日：2007-12-18

Applicant: ASTRAZENECA AB ,  ASTEX THERAPEUTICS LTD ,  BERG, Stefan ,  HALLBERG, Jesper ,  HÖGDIN, Katharina ,  KARLSTRÖM, Sofia ,  KERS, Annika ,  PLOBECK, Niklas ,  RAKOS, Laszlo

Inventor： BERG, Stefan ,  HALLBERG, Jesper ,  HÖGDIN, Katharina ,  KARLSTRÖM, Sofia ,  KERS, Annika ,  PLOBECK, Niklas ,  RAKOS, Laszlo

IPC: C07D405/04 ,  A61K31/4178 ,  A61P25/28

CPC classification number: C07D405/04

Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Abstract translation: 本发明涉及具有以下结构式I的新化合物及其药学上可接受的盐，组合物和使用方法。 这些新化合物提供认知障碍，阿尔茨海默病，神经变性和痴呆症的治疗或预防。

公开(公告)号：WO2011002409A1

公开(公告)日：2011-01-06

申请号：PCT/SE2010/050761

申请日：2010-07-02

Applicant: ASTRAZENECA AB ,  HOLENZ, Jörg ,  KARLSTRÖM, Sofia ,  KIHLSTRÖM, Jacob ,  KOLMODIN, Karin ,  LINDSTRÖM, Johan ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SWAHN, Britt-Marie ,  VON BERG, Stefan

Inventor： HOLENZ, Jörg ,  KARLSTRÖM, Sofia ,  KIHLSTRÖM, Jacob ,  KOLMODIN, Karin ,  LINDSTRÖM, Johan ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SWAHN, Britt-Marie ,  VON BERG, Stefan

IPC: C07D487/04 ,  A61K31/4985 ,  A61P25/28

CPC classification number: C07D487/04

Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Abstract translation: 本发明涉及新的式（I）化合物及其药物组合物。 此外，本发明涉及用于治疗和/或预防诸如唐氏综合征，β-淀粉样变性血管病，例如但不限于脑淀粉样血管病或遗传性脑出血的Aβ相关病理学的治疗方法，与认知障碍相关的疾病 例如但不限于MCI（“轻度认知障碍”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与诸如阿尔茨海默病或痴呆症的疾病相关的神经变性，包括混合血管和退行性起源的痴呆， 老年性痴呆，老年性痴呆和与帕金森病相关的痴呆，进行性核上性麻痹或皮质基底变性。

公开(公告)号：WO2008076044A1

公开(公告)日：2008-06-26

申请号：PCT/SE2007/001117

申请日：2007-12-18

Applicant: ASTRAZENECA AB ,  ASTEX THERAPEUTICS LTD ,  BERG, Stefan ,  HALLBERG, Jesper ,  HÖGDIN, Katharina ,  KARLSTRÖM, Sofia ,  KERS, Annika ,  PLOBECK, Niklas ,  RAKOS, Laszlo

Inventor： BERG, Stefan ,  HALLBERG, Jesper ,  HÖGDIN, Katharina ,  KARLSTRÖM, Sofia ,  KERS, Annika ,  PLOBECK, Niklas ,  RAKOS, Laszlo

IPC: C07D405/04 ,  A61K31/4178 ,  A61P25/28

CPC classification number: C07D405/04

Abstract: This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Abstract translation: 本发明涉及具有以下结构式（I）的新化合物及其药学上可接受的盐，组合物和使用方法。 这些新化合物提供了认知障碍，阿尔茨海默病，神经变性和痴呆症的治疗或预防。

公开(公告)号：WO2012087237A1

公开(公告)日：2012-06-28

申请号：PCT/SE2011/051555

申请日：2011-12-21

Applicant: ASTRAZENECA AB ,  CSJERNYIK, Gabor ,  KARLSTRÖM, Sofia ,  KERS, Annika ,  KOLMODIN, Karin ,  NYLÖF, Martin ,  ÖHBERG, Liselotte ,  RAKOS, Laszlo ,  SANDBERG, Lars ,  SEHGELMEBLE, Fernando ,  SÖDERMAN, Peter ,  SWAHN, Britt-Marie ,  VON BERG, Stefan

Inventor： CSJERNYIK, Gabor ,  KARLSTRÖM, Sofia ,  KERS, Annika ,  KOLMODIN, Karin ,  NYLÖF, Martin ,  ÖHBERG, Liselotte ,  RAKOS, Laszlo ,  SANDBERG, Lars ,  SEHGELMEBLE, Fernando ,  SÖDERMAN, Peter ,  SWAHN, Britt-Marie ,  VON BERG, Stefan

IPC: C07D491/107 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4439 ,  A61K31/506 ,  A61P25/28 ,  C07D401/04 ,  C07D235/02 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D491/20

CPC classification number: A61K31/497 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00 ,  C07D235/02 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D471/04 ,  C07D491/107 ,  C07D491/20

Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

Abstract translation: 本发明涉及式（I）化合物及其药物组合物。 此外，本发明涉及用于治疗和/或预防β相关病理学的治疗方法，例如唐氏综合征，β-淀粉样变性血管病，例如但不限于脑淀粉样血管病或遗传性脑出血，与认知相关的疾病 损伤例如但不限于MCI（“轻度认知障碍”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与诸如阿尔茨海默氏病或​​痴呆的疾病相关的神经变性，包括混合血管和退行性来源的痴呆，前 老年痴呆症，老年痴呆症和与帕金森病相关的痴呆症。

公开(公告)号：WO2010056195A1

公开(公告)日：2010-05-20

申请号：PCT/SE2009/051293

申请日：2009-11-13

Applicant: ASTRAZENECA AB ,  HOLENZ, Jörg ,  KARLSTRÖM, Sofia ,  KIHLSTRÖM, Jacob ,  KOLMODIN, Karin ,  RAKOS, Laszlo ,  SÖDERMAN, Peter ,  SWAHN, Britt-Marie ,  VON BERG, Stefan ,  VON KIESERITZKY, Fredrik

Inventor： HOLENZ, Jörg ,  KARLSTRÖM, Sofia ,  KIHLSTRÖM, Jacob ,  KOLMODIN, Karin ,  RAKOS, Laszlo ,  SÖDERMAN, Peter ,  SWAHN, Britt-Marie ,  VON BERG, Stefan ,  VON KIESERITZKY, Fredrik

IPC: C07D471/04 ,  A61K31/4745 ,  A61P25/28

CPC classification number: C07D471/04 ,  A61K31/4745

Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Abstract translation: 本发明涉及新的式（I）化合物及其药物组合物。 此外，本发明涉及用于治疗和/或预防诸如唐氏综合征，β-淀粉样变性血管病等Aβ型相关病症的治疗方法，但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病 例如但不限于MCI（“轻度认知障碍”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与诸如阿尔茨海默病或痴呆症的疾病相关的神经变性，包括混合血管和退行性起源的痴呆， 老年性痴呆，老年性痴呆和与帕金森病相关的痴呆，进行性核上性麻痹或皮质基底变性。

公开(公告)号：WO2007149033A1

公开(公告)日：2007-12-27

申请号：PCT/SE2007/000601

申请日：2007-06-20

Applicant: ASTRAZENECA AB ,  ASTEX THERAPEUTICS LTD. ,  ARNOLD, James ,  BERG, Stefan ,  CHESSARI, Gianni ,  CONGREVE, Miles ,  EDWARDS, Phil ,  HOLENZ, Jörg ,  KERS, Annika ,  KOLMODIN, Karin ,  MURRAY, Christopher ,  PATEL, Sahil ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SYLVESTER, Mark ,  ÖHBERG, Liselotte

Inventor： ARNOLD, James ,  BERG, Stefan ,  CHESSARI, Gianni ,  CONGREVE, Miles ,  EDWARDS, Phil ,  HOLENZ, Jörg ,  KERS, Annika ,  KOLMODIN, Karin ,  MURRAY, Christopher ,  PATEL, Sahil ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SYLVESTER, Mark ,  ÖHBERG, Liselotte

IPC: C07D209/44 ,  A61K31/4035 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/506 ,  A61P25/28 ,  C07D401/10 ,  C07D403/10 ,  C07D407/14

CPC classification number: A61K31/4035 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/506 ,  C07D209/44 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D405/14 ,  C07D513/04

Abstract: This invention relates to novel compounds having the structural formula I and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Abstract translation: 本发明涉及具有结构式I的新化合物及其药学上可接受的盐，组合物和使用方法。 这些新化合物提供了认知障碍，阿尔茨海默病，神经变性和痴呆症的治疗或预防。

公开(公告)号：WO2004096927A1

公开(公告)日：2004-11-11

申请号：PCT/NO2004/000115

申请日：2004-04-23

Applicant: JOTUN AS ,  BÖRVE, Anita ,  DAHLING, Marit ,  AUKRUST, Inger Reidun F. ,  RAKOS, Laszlo ,  NESET, Siren M.

Inventor： BÖRVE, Anita ,  DAHLING, Marit ,  AUKRUST, Inger Reidun F. ,  RAKOS, Laszlo ,  NESET, Siren M.

IPC: C09D5/16

CPC classification number: C09D5/1662 ,  C08G67/04 ,  C09D173/02

Abstract: The invention concerns novel polyanhydrides with the general formula -(A) a - (B) b - (C) c -, a method for preparation of the novel anhydrides, use of the novel anhydrides in paint and a paint containing the novel anhydrides.

Abstract translation: 本发明涉及具有以下通式的新型聚酐：（A）a - （B）b - （C）c - ，新型酸酐的制备方法，涂料中新型酸酐的使用和含有新型酸酐的涂料。

公开(公告)号：WO2012064269A1

公开(公告)日：2012-05-18

申请号：PCT/SE2011/051341

申请日：2011-11-10

Applicant: ASTRAZENECA AB ,  MACSÁRI, István ,  PAULSEN, Kim ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SWAHN, Britt-Marie ,  VON BERG, Stefan ,  WALDMAN, Magnus

Inventor： MACSÁRI, István ,  PAULSEN, Kim ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SWAHN, Britt-Marie ,  VON BERG, Stefan ,  WALDMAN, Magnus

IPC: C07D498/04 ,  A61K31/553 ,  A61P25/28

CPC classification number: A61K31/553 ,  C07D498/04

Abstract: The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Αβ-related diseases.

Abstract translation: 本发明涉及新的式（I）化合物及其药学上可接受的盐，包含所述化合物的药物组合物，所述化合物的制备方法及其作为用于治疗和/或预防β相关疾病的药物的用途。

公开(公告)号：WO2010056196A1

公开(公告)日：2010-05-20

申请号：PCT/SE2009/051295

申请日：2009-11-13

Applicant: ASTRAZENECA AB ,  HOLENZ, Jörg ,  KARLSTRÖM, Sofia ,  KOLMODIN, Karin ,  LINDSTRÖM, Johan ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SÖDERMAN, Peter ,  SWAHN, Britt-Marie ,  VON BERG, Stefan

Inventor： HOLENZ, Jörg ,  KARLSTRÖM, Sofia ,  KOLMODIN, Karin ,  LINDSTRÖM, Johan ,  RAKOS, Laszlo ,  ROTTICCI, Didier ,  SÖDERMAN, Peter ,  SWAHN, Britt-Marie ,  VON BERG, Stefan

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61P25/28 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10

Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Abstract translation: 本发明涉及新的式（I）化合物及其药物组合物。 此外，本发明涉及用于治疗和/或预防诸如唐氏综合征，β-淀粉样变性血管病等Aβ型相关病症的治疗方法，但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病 例如但不限于MCI（“轻度认知障碍”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与诸如阿尔茨海默病或痴呆症的疾病相关的神经变性，包括混合血管和退行性起源的痴呆， 老年性痴呆，老年性痴呆和与帕金森病相关的痴呆，进行性核上性麻痹或皮质基底变性。